Vaccines, Blood & Biologics


STN: BL 125466
Proper Name: Antihemophilic Factor (Recombinant)
Tradename: Novoeight
Manufacturer: Novo Nordisk 


  • For adults, adolescents, and children with hemophilia A for (1) the control and prevention of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Note:  The FDA approval of Novoeight is an activity that is funded under FDA’s user fee program in the Center for Biologics Evaluation and Research. Some FDA activities that do not rely on annual appropriations are continuing during the government shutdown.

Page Last Updated: 11/18/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.